Creation of the BioBank, Early Detection and Discovery Biomarkers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Dianna Larson, William Beaumont Hospitals
ClinicalTrials.gov Identifier:
NCT00901680
First received: May 13, 2009
Last updated: August 20, 2012
Last verified: August 2012
  Purpose

To establish a multidisciplinary research structure for tissue repository that facilitates projects that bridge specialties that normally may or may not interact.


Condition
Pancreatic Cancer
Head and Neck Cancer
Breast Cancer

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Creation of the BioBank,To Establish a Multidisciplinary Research Structure That Facilitates Projects That Bridge Specialties That Normally May or May Not Interact.

Resource links provided by NLM:


Further study details as provided by William Beaumont Hospitals:

Biospecimen Retention:   Samples With DNA

Biospecimens to be retained are tissue, blood, whole blood, DNA, RNA, urine saliva,cerebral spinal fluid, amniotic fluid.


Enrollment: 3028
Study Start Date: August 2008
Study Completion Date: January 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Detailed Description:

To establish a multidisciplinary research structure that facilitates projects that bridge specialties that normally may or may not interact. The tissue bank will build the platform for a novel application of translational research that links cutting edge molecular laboratory techniques to clinical outcome studies in a fast and direct manner. Tissue banks can be used for numerous discovery applications such as the identification and structural characterization of human genes, expression analysis, or discovery proteomics. Biological specimens, when coupled with standardized treatment and outcome data, will be essential resources for the identification, characterization, and validation of biomarkers that are predictive of disease and treatment.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Population male/female from inpatient and outpatient hospital settings or doctor offices..

Criteria

Inclusion Criteria:

  • Male and female volunteers

Exclusion Criteria:

  • N/A volunteers
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00901680

Locations
United States, Michigan
William Beaumont Hospitals
Royal Oak, Michigan, United States, 48370
Sponsors and Collaborators
William Beaumont Hospitals
Investigators
Principal Investigator: George Wilson, PhD William Beaumont Hospitals
  More Information

Additional Information:
No publications provided

Responsible Party: Dianna Larson, George Wilson PhD, William Beaumont Hospitals
ClinicalTrials.gov Identifier: NCT00901680     History of Changes
Other Study ID Numbers: HIC 2008-180
Study First Received: May 13, 2009
Last Updated: August 20, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by William Beaumont Hospitals:
Tissue Bank

Additional relevant MeSH terms:
Breast Neoplasms
Head and Neck Neoplasms
Pancreatic Neoplasms
Breast Diseases
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Neoplasms
Neoplasms by Site
Pancreatic Diseases
Skin Diseases

ClinicalTrials.gov processed this record on October 22, 2014